[New drugs for substitution treatment of opioid dependence. Buprenorphine and 1-alpha-acetylmethadol (LAAM) ].
Two new long-acting opioid agonists have recently been introduced for the substitutional treatment of opioid-dependent patients: Orlaam (LAAM) and Subutex (buprenorphine). Both have a dose-related duration of action two to three times that of methadone, and can be given only three times a week instead of daily, thus reducing the need for take-home doses. Further, the longer duration of action provides a smoother blood level with fewer fluctuations between doses. With the availability of buprenorphine and LAAM as alternatives to methadone, agonist treatment can be more differentiated, and one can hope that this will increase the quality of the treatment.
Petersen
H
H
Københavns Kommune, Familie- og Arbejdsmarkedsforvaltningen.
Skauge
L
L
Svejsø
J
J
Ege
P P
PP
D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D002047:Buprenorphine / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D018849:Controlled Clinical Trials as Topic; D004347:Drug Interactions; D006801:Humans; D008692:Methadyl Acetate / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D009293:Opioid-Related Disorders / Q000188:drug therapy* / Q000534:rehabilitation
D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D002047:Buprenorphine; D008692:Methadyl Acetate